<DOC>
	<DOCNO>NCT02885623</DOCNO>
	<brief_summary>This study evaluate clinical significance CX3CR1-expressing myeloid lymphoid cell patient hematologic malignancy . Tumor cell either express membrane molecule release tumor-derived soluble factor able alter myelopoiesis lymphopoiesis . Myeloid cell express CD11b play critical role sustain cancer progression . Also , fractalkine ( CX3CL1 ; Fkn ) /CX3CR1 axis play important function pathophysiology various form cancer . Fkn known ligand CX3CR1 , trigger recruitment CX3CR1-positive cell unique receptor , CX3CR1 . Therefore , investigator focus prognostic significance CD11b+ myelo-monocytic cell express CX3CR1 CD3+ lymphoid cell express CX3CR1 clinical outcome newly diagnose Diffuse Large B-cell Lymphoma ( DLBCL ) Multiple myeloma ( MM ) .</brief_summary>
	<brief_title>Role CX3CR1-expressing Cells Hematologic Malignancy</brief_title>
	<detailed_description>Bone marrow aspirate obtain newly diagnose MM DLBCL patient time diagnosis relapse . Peripheral blood obtain time diagnosis , finish treatment , 3 month treatment relapse . The investigator analyze cell fraction CD11b+ CX3CR1+ cell CD3+CX3CR1+ cell blood sample flowcytometry . The investigator find relationship test cell clinical outcome MM DLBCL .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Subject newly diagnose multiple myeloma . Subject newly diagnose diffuse large B cell lymphoma . History hematologic malignancy History previous chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>